-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 9, Yiling Pharmaceutical closed at 29.
62 yuan / share
at noon.
Since the same period in 2020, the three-year compound growth rate of Yiling Pharmaceutical's stock price has reached 34.
77%.
The steadily rising stock price is a concentrated reflection
of Ling's achievements in products, performance and R&D, and the continuous improvement of the company's basic market.
62 yuan / share
at noon.
Since the same period in 2020, the three-year compound growth rate of Yiling Pharmaceutical's stock price has reached 34.
77%.
The steadily rising stock price is a concentrated reflection
of Ling's achievements in products, performance and R&D, and the continuous improvement of the company's basic market.
In terms of products, Yiling Pharmaceutical has developed a series of patented traditional Chinese medicines
with independent intellectual property rights around six categories of diseases with high cardiovascular and cerebrovascular diseases, diabetes, respiratory, tumor, neurological and urinary incidence, and large market dosage.
At present, Yiling Pharmaceutical has 13 patented new drugs, of which 8 are listed in the national medical insurance catalogue and 5 are listed in the national essential drug list, which provides an important driving force
for the company's performance growth.
with independent intellectual property rights around six categories of diseases with high cardiovascular and cerebrovascular diseases, diabetes, respiratory, tumor, neurological and urinary incidence, and large market dosage.
At present, Yiling Pharmaceutical has 13 patented new drugs, of which 8 are listed in the national medical insurance catalogue and 5 are listed in the national essential drug list, which provides an important driving force
for the company's performance growth.
In terms of performance, the third quarter report of 2022 shows that the net profit attributable to the parent of Yiling Pharmaceutical in the first three quarters was 1.
41 billion yuan, an increase of 15.
58% over the same period last year, and a three-year compound growth rate of 34.
99%; Net profit net of non-attributable parent was 1.
42 billion yuan, an increase of 20.
6% over the same period last year, and a three-year compound growth rate of 37.
92%.
41 billion yuan, an increase of 15.
58% over the same period last year, and a three-year compound growth rate of 34.
99%; Net profit net of non-attributable parent was 1.
42 billion yuan, an increase of 20.
6% over the same period last year, and a three-year compound growth rate of 37.
92%.
Figure 1: Source: Institute of Listed Companies in the Financial Sector
In terms of R&D, according to CHOICE data, in the first three quarters of 2022, Yiling Pharmaceutical's R&D expenses were 552 million yuan, a year-on-year increase of 2.
6%.
From 2018 to the first three quarters of 2022, Yiling Pharmaceutical's R&D expenses continued to rise, with a compound growth rate of 32.
33%.
6%.
From 2018 to the first three quarters of 2022, Yiling Pharmaceutical's R&D expenses continued to rise, with a compound growth rate of 32.
33%.
Figure 2: Source: Institute of Listed Companies in the Financial Sector
In addition, on January 4, the State Food and Drug Administration issued Several Measures on Further Strengthening the Scientific Supervision of Traditional Chinese Medicines and Promoting the Inheritance, Innovation and Development of Traditional Chinese Medicines, which proposed to further support the research and development of
traditional Chinese medicine preparations in medical institutions.
As a representative enterprise of TCM innovation and transformation that has created an integrated TCM academic innovation and transformation model of "theory + clinical + new drug + experiment + evidence-based", and combines traditional theoretical innovation of TCM with modern science and technology, it is expected to stand out in the wave of TCM innovation and provide a solid fortress for the sustainable and healthy development of the company
。
traditional Chinese medicine preparations in medical institutions.
As a representative enterprise of TCM innovation and transformation that has created an integrated TCM academic innovation and transformation model of "theory + clinical + new drug + experiment + evidence-based", and combines traditional theoretical innovation of TCM with modern science and technology, it is expected to stand out in the wave of TCM innovation and provide a solid fortress for the sustainable and healthy development of the company
。
